UV Clinical has developed a platform technology for microbial reduction on the inner surfaces of medical tubes. The medical device uses UVC light transmitted and distributed through the lumen of medical tubes.

The company was founded in 2017 as a spin-off from the Technical University of Denmark (DTU). Having successfully completed the proof-of-concept stage, our immediate objective is to secure FDA approval and introduce the device to the market, unlocking its substantial potential. 

UV Clinical is backed by 80+ shareholders across 15 countries, including med-tech investors, industry specialists, and strategic partners. Together, they form the UV Clinical family - a strong, international investor community supporting the company’s global scale-up and commercialization. The largest shareholder is CEO, Rolf H. Sprunk-Jansen, who actively leads the company toward FDA clearance and market launch.

UV Clinical

Org chart

Teams

Offices